Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
The use of niacin, alone and in combination, for the treatment of dyslipidemia in patients with or at risk for coronary heart disease (CHD), is discussed. Cardiovascular risk is independently predicted not only by high levels of low-density lipoprotein cholesterol (LDL-C), but also low levels of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides. Moreover, we now understand that LDL particle size and number are associated with differing levels of atherogenicity. Metabolic syndrome, increasingly being recognized as a marker for elevated cardiovascular risk, is associated with atherogenic dyslipidemia characterized by low HDL-C, high triglycerides, and small, dense LDL particles. Controlled clinical studies have shown that niacin therapy effectively increases HDL-C and lowers triglyceride and LDL-C levels while causing a shift toward larger, less atherogenic LDL particles. Niacin, alone or in combination, prevents progression and promotes regression of coronary atherogenic lesions and significantly reduces CHD-related morbidity and mortality. Statin monotherapy causes modest increases in HDL-C and decreases triglycerides, while more potently reducing LDL-C. Combinations of lipid-modifying agents may better address the full spectrum of lipoprotein abnormalities in some patients. Investigations have shown that combining statin therapy with niacin results in additive improvement in the major lipids and lipoproteins and improves clinical outcome. With recently broadened treatment recommendations, it seems likely that combination therapy will be increasingly deemed the appropriate choice for addressing a range of lipid abnormalities.
Ito
Matthew K
MK
University of the Pacific, Thomas J. Long School of Pharmacy and Health Sciences, 3350 La Jolla Village Drive, San Diego, CA 92161-0002, USA. uopito@aol.com
D002626:Chemistry, Pharmaceutical; D008076:Cholesterol, HDL / Q000009:adverse effects / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D008074:Lipoproteins / Q000378:metabolism; D009525:Niacin / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010353:Patient Education as Topic; D012206:Rhabdomyolysis / Q000139:chemically induced; D013810:Therapeutic Equivalency; D014280:Triglycerides / Q000009:adverse effects / Q000378:metabolism*
D008076:Cholesterol, HDL; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D014280:Triglycerides; D009525:Niacin